BioSpace News Archive

NewHaptics, an innovative tactile display technology company, announced it has been awarded a Phase II Small Business Innovation Research (SBIR) grant funded by the U.S. National Institutes of Health (NIH).

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), today announced that its chief executive officer, Nima Farzan, will participate in the Piper Sandler Heartland Summit as part of the panel “Healthcare Politics: FDA Proposals from Optimus, to ORBIS to RTOR and CONFIRM – How Might These Proposals Impact Oncology Drug Development and Implications?” on Thursday, September 22, 2022 at 11:30 a.m. C.T.

Spero Therapeutics, Inc. announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer.

Xilio Therapeutics, Inc., a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, announced the appointment of Tomas J. Heyman to the company’s board of directors.

Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced the company will be participating in the upcoming Lytham Partners Fall Investor Conference.

Invitae, a leading medical genetics company, joined other clinical experts in releasing a new commentary in Journal of Clinical Oncology Precision Oncology, underscoring the importance of universal germline testing for all patients with cancer.

Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the International Symposium on Biopolymers (“ISBP”) 2022 Conference.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present seven abstracts from across its neuroscience portfolio at the 35th annual Psych Congress 2022, being held September 17-20, 2022.

Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved significant improvements in disease activity when switched to Sofusa lymphatic delivery.

TempraMed is launching a new-generation insulin pen-cap temperature shield that takes its exclusive, industry-standard insulin protection to new levels of efficacy and convenience.